Multiscale Modeling of Inflammation, Metabolism, and Pharmacological Control: Coupled Dynamics of Tregs, Cytokines, Proteostasis, and Glucose-Insulin Regulation

Chaperone systems centered on HSP70 and HSP90 constitute a fundamental layer of cellular regulation operating under non-equilibrium dynamics, where continuous energy consumption sustains proteome stability far from thermodynamic equilibrium. In this framework, proteostasis emerges not as a static condition but as a dynamically regulated proteostasis landscape, shaped by ATP-dependent conformational transitions and adaptive network reconfiguration. At the molecular scale, HSP70 functions through rapid, energy-dependent binding and release cycles, coupling ATP hydrolysis to substrate affinity modulation. This mechanism enables selective stabilization of unfolded or metastable protein states, effectively lowering the probability of aggregation by kinetically trapping intermediates along the folding pathway. In contrast, HSP90 operates on a slower timescale, stabilizing high-energy conformational states of signaling proteins, thereby acting as a buffer of phenotypic variation and a regulator of network robustness. From a biophysical perspective, these chaperone-mediated processes can be interpreted as driven transitions across a rugged free-energy landscape, where ATP binding and hydrolysis reshape local minima and transition barriers. This results in an energy-dependent conformational cycling that maintains functional protein ensembles under fluctuating environmental and intracellular constraints, including thermal stress, oxidative imbalance, and inflammatory signaling. Importantly, this chaperone network is functionally integrated with ubiquitin-mediated quality control systems and metabolic regulators. Proteins such as TRIM21 and TRIM47 act as E3 ubiquitin ligases that selectively tag irreversibly damaged substrates, coupling chaperone-mediated refolding attempts to degradation pathways. Concurrently, metabolic sensors such as SIRT1 modulate chaperone activity and stress responses through NAD⁺-dependent deacetylation, linking cellular energetic state to proteostasis capacity. This integrated system defines a multi-layer regulatory architecture, where chaperones, ubiquitin ligases, and metabolic enzymes collectively maintain network-level stability under perturbation. Under stress conditions—whether environmental (e.g., heat, toxins) or intrinsic (e.g., proteotoxic load, genomic instability)—the system undergoes a coordinated shift characterized by increased chaperone flux, altered folding kinetics, and enhanced protein turnover. From a pharmacological standpoint, this non-equilibrium proteostasis network represents a highly tunable target space. Small molecules that inhibit the ATP-binding domain of HSP90 disrupt the stabilization of oncogenic client proteins, while modulators of HSP70 alter folding kinetics and stress tolerance thresholds. Additionally, targeting TRIM-mediated ubiquitination or SIRT1-dependent metabolic regulation provides indirect mechanisms to reshape the proteostasis landscape, offering combinatorial strategies for diseases associated with proteotoxic stress, including cancer and neurodegeneration. Taken together, HSP70 and HSP90 do not merely prevent protein misfolding; they function as active regulators of energy flow and information stability within cellular networks, ensuring that structural and functional integrity is preserved despite continuous perturbation. This perspective positions proteostasis as an emergent property of energy-driven, network-coupled molecular processes, rather than a passive equilibrium state.